Novartis, Roche back US efforts to lower drug costs amid talk of pricing deal
I'm PortAI, I can summarize articles.
Swiss pharmaceutical companies Novartis and Roche are supporting U.S. efforts to reduce drug costs and are in discussions with the Trump administration to reach a pricing deal. This follows similar agreements by other companies like Pfizer and AstraZeneca. Novartis and Roche emphasize the importance of fair pricing and innovation, while a potential deal is reportedly nearing completion.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments